Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 220.127.116.11) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
Iduronate 2-sulfatase (IDS) is a sulfatase enzyme associated with Hunter syndrome. Iduronate 2-sulfatase is required for the lysosomal degradation of heparan sulfate and dermatan sulfate. Mutations in this X-chromosome gene that result in enzymatic deficiency lead to Hunter syndrome.
In 2018, the global Iduronate 2 Sulfatase market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Iduronate 2 Sulfatase status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Iduronate 2 Sulfatase development in United States, Europe and China.
The key players covered in this study
Market segment by Type, the product can be split into
Alpha L Iduronate Sulfate Sulfatase
Market segment by Application, split into
Ambulatory Surgical Centers
Market segment by Regions/Countries, this report covers
Central & South America
The study objectives of this report are:
To analyze global Iduronate 2 Sulfatase status, future forecast, growth opportunity, key market and key players.
To present the Iduronate 2 Sulfatase development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Iduronate 2 Sulfatase are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.